Portal de Periódicos da CAPES

Systemic increase in type I interferon activity in Sjögren's syndrome: A putative role for plasmacytoid dendritic cells

2008; Wiley; Volume: 38; Issue: 7 Linguagem: Inglês

10.1002/eji.200738008

1521-4141

Manon E. Wildenberg, Cornelia G van Helden-Meeuwsen, J.P. van de Merwe, Hemmo A. Drexhage, Marjan A. Versnel,

Systemic Lupus Erythematosus Research

In the salivary glands of primary Sjögren's syndrome (pSjS) patients, type I IFN activity is increased, but systemic levels of type I IFN proteins are rarely detected. This study focused on the systemic activity of type I IFN in pSjS, as well as the role of peripheral plasmacytoid dendritic cells (pDC). Monocytes obtained from pSjS patients showed an increased expression of 40 genes. Twenty-three of these genes (58%), including IFI27, IFITM1, IFIT3 and IFI44, were inducible by type I IFN. pSjS serum had an enhanced capability of inducing IFI27, IFITM1, IFIT3 and IFI44 in the monocytic cell line THP-1, likely due to the action of IFN-beta. This effect could be inhibited by blocking the type I IFN receptor, supporting a high type I IFN bioactivity in pSjS serum. In addition, circulatory pDC showed increased expression of CD40. This expression was correlated to the expression level of the type I IFN-regulated genes IFI27 and IFITM1 in monocytes of the same individual. This study indicates that the increased type I IFN activity observed in pSjS patients is not only a local but also a systemic phenomenon and points to pDC as a possible source of this activity.